2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year

366
Comment
Favorite

2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year

Motley Fool2022-12-19

You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

366

Report

Comment

Deonc
·2022-12-19
Ok
Reply
Like
Report
Deonc
·2022-12-19
Good sharing
Reply
1
Report
Tbun
·2022-12-19
Ok
Reply
1
Report
JustLe
·2022-12-19
Ok
Reply
3
Report
Fold Replies
- JustLe:
  Ok
  2022-12-19
  Reply
  Report
OO_898
·2022-12-19
Like
Reply
4
Report
EdwardKarchi
·2022-12-19
Like
Reply
2
Report
Hayleyxn
·2022-12-19
OK
Reply
4
Report
Fold Replies
- EdwardKarchi:
  Ok
  2022-12-19
  Reply
  Report
- Hayleyxn:
  OK
  2022-12-19
  Reply
  Report
MickeyBond
·2022-12-19
Ok
Reply
2
Report
weekendnote
·2022-12-19
Ok
Reply
4
Report
V K
·2022-12-19
Pls like tyvm[Happy]
Reply
3
Report
kkennn
·2022-12-19
Upp
Reply
3
Report
Fold Replies
- Princessleo:
  Yo
  2022-12-19
  Reply
  Report
TTM Investor
·2022-12-19
Ok
Reply
6
Report
YsL
·2022-12-19
Like
Reply
6
Report
SimonTan91
·2022-12-19
Oo
Reply
7
Report
Fold Replies
- kkennn:
  Ok
  2022-12-19
  Reply
  Report
soosoo
·2022-12-19
Ok
Reply
6
Report
Fold Replies
- SimonTan91:
  ok
  2022-12-19
  Reply
  Report
Ahsiang
·2022-12-19
Sure anot
Reply
7
Report
Fold Replies
- Meowlisa:
  Ok
  2022-12-19
  Reply
  Report
- Alfred8189:
  Ok
  2022-12-19
  Reply
  Report
- jingabel:
  k
  2022-12-19
  Reply
  Report
Butt3rc00ki3
·2022-12-19
Like
Reply
8
Report
Fold Replies
- Mad Hatter:
  Ok
  2022-12-19
  Reply
  Report
ops22
·2022-12-19
Ok
Reply
6
Report
Fold Replies
- Veldin:
  Sew
  2022-12-19
  Reply
  Report
- ZachLoh:
  Ok
  2022-12-19
  Reply
  Report
Dragonroar
·2022-12-19
Wow
Reply
9
Report
Fold Replies
- 鸟雨花香:
  👍
  2022-12-20
  Reply
  Report
- ops22:
  ok
  2022-12-19
  Reply
  Report
ColeHii
·2022-12-19
🇦🇷
Reply
9
Report
Fold Replies
- LuciusCY:
  ok
  2022-12-19
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2292286774?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-12-19 12:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2292286774","market":"us","top_or_hot":-1,"title":"2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year","media":"Motley Fool","content":"<div>\n<p>You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-19 12:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TDOC","symbol_name":"Teladoc Health Inc.","start_time":0,"source_url":"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/","article_id":"2292286774","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2292286774","pubTimestamp":1671422971,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"These stocks look cheap -- especially considering their long-term potential.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"TDOC":"Teladoc Health Inc.","ABT":"雅培"},"translate_title":"2022年便宜货购物：新年前购买2只智能股票","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABT":0.9,"TDOC":0.9},"content_text":"You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.\"But what if these stocks fall even further?\" you might wonder. Well, it's impossible to effectively time the market, and it's a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you'll still benefit even if you didn't buy them at their cyclical low points.If you're ready to give this winning strategy a try, here are two smart stocks I'd recommend buying before the new year.1. Teladoc HealthTeladoc Health stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc's visits and revenue climbed by triple-digit percentages.But the company has demonstrated it isn't a pandemic-only business. Teladoc's revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.The third quarter brought investors some good news. Teladoc's loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it's expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.Today, Teladoc shares are trading at their cheapest level ever in relation to sales. This is a major bargain considering the company's long-term potential.2. Abbott LaboratoriesThere are two reasons to like Abbott Laboratories. First, let's talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it's particularly nice to have this guaranteed income during tough market times.And Abbott isn't just a dividend stock -- it's a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.Abbott has grown its free cash flow and return on invested capital over time.ABT Free Cash Flow data by YCharts.And it recently increased its full-year earnings-per-share forecast.All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today's valuation of 20 times forward earnings estimates, Abbott's a stock you won't want to miss.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[{"id":9926909473,"gmtCreate":1671434617992,"gmtModify":1676538535791,"author":{"id":"3569316529855154","authorId":"3569316529855154","name":"Deonc","avatar":"https://static.tigerbbs.com/d9aa45dd2eb58357f6477dcfb99d1415","vip":1,"crmLevel":3,"crmLevelSwitch":1},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9926909473","repostId":2292286774,"repostType":4,"repost":{"id":"2292286774","pubTimestamp":1671422971,"share":"https://www.laohu8.com/m/news/2292286774?lang=&edition=full","pubTime":"2022-12-19 12:09","market":"us","language":"en","title":"2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2292286774","media":"Motley Fool","summary":"These stocks look cheap -- especially considering their long-term potential.","content":"<html><head></head><body><p>You may see a lot of bargains in the shops and online this season. But there&#39;s an even better place to find a good deal these days. I&#39;m talking about the stock market. This year&#39;s long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.</p><p><i>&#34;But what if these stocks fall even further?&#34;</i> you might wonder. Well, it&#39;s impossible to effectively time the market, and it&#39;s a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you&#39;ll still benefit even if you didn&#39;t buy them at their cyclical low points.</p><p>If you&#39;re ready to give this winning strategy a try, here are two smart stocks I&#39;d recommend buying before the new year.</p><h2>1. Teladoc Health</h2><p><b>Teladoc Health</b> stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc&#39;s visits and revenue climbed by triple-digit percentages.</p><p>But the company has demonstrated it isn&#39;t a pandemic-only business. Teladoc&#39;s revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.</p><p>Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.</p><p>So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.</p><p>The third quarter brought investors some good news. Teladoc&#39;s loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.</p><p>Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it&#39;s expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.</p><p>Today, Teladoc shares are trading at their cheapest level <i>ever</i> in relation to sales. This is a major bargain considering the company&#39;s long-term potential.</p><h2>2. Abbott Laboratories</h2><p>There are two reasons to like <b>Abbott Laboratories</b>. First, let&#39;s talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it&#39;s particularly nice to have this guaranteed income during tough market times.</p><p>And Abbott isn&#39;t just a dividend stock -- it&#39;s a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.</p><p>Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.</p><p>Abbott has grown its free cash flow and return on invested capital over time.</p><p><img src=\"https://static.tigerbbs.com/053ae37cdf88229d770c12540a333184\" tg-width=\"720\" tg-height=\"463\" referrerpolicy=\"no-referrer\"/></p><p>ABT Free Cash Flow data by YCharts.</p><p>And it recently increased its full-year earnings-per-share forecast.</p><p>All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today&#39;s valuation of 20 times forward earnings estimates, Abbott&#39;s a stock you won&#39;t want to miss.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-19 12:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABT":"雅培","TDOC":"Teladoc Health Inc."},"source_url":"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2292286774","content_text":"You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.\"But what if these stocks fall even further?\" you might wonder. Well, it's impossible to effectively time the market, and it's a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you'll still benefit even if you didn't buy them at their cyclical low points.If you're ready to give this winning strategy a try, here are two smart stocks I'd recommend buying before the new year.1. Teladoc HealthTeladoc Health stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc's visits and revenue climbed by triple-digit percentages.But the company has demonstrated it isn't a pandemic-only business. Teladoc's revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.The third quarter brought investors some good news. Teladoc's loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it's expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.Today, Teladoc shares are trading at their cheapest level ever in relation to sales. This is a major bargain considering the company's long-term potential.2. Abbott LaboratoriesThere are two reasons to like Abbott Laboratories. First, let's talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it's particularly nice to have this guaranteed income during tough market times.And Abbott isn't just a dividend stock -- it's a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.Abbott has grown its free cash flow and return on invested capital over time.ABT Free Cash Flow data by YCharts.And it recently increased its full-year earnings-per-share forecast.All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today's valuation of 20 times forward earnings estimates, Abbott's a stock you won't want to miss.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9926900071,"gmtCreate":1671434292394,"gmtModify":1676538535736,"author":{"id":"3569316529855154","authorId":"3569316529855154","name":"Deonc","avatar":"https://static.tigerbbs.com/d9aa45dd2eb58357f6477dcfb99d1415","vip":1,"crmLevel":3,"crmLevelSwitch":1},"htmlText":"Good sharing","listText":"Good sharing","text":"Good sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9926900071","repostId":2292286774,"repostType":4,"repost":{"id":"2292286774","pubTimestamp":1671422971,"share":"https://www.laohu8.com/m/news/2292286774?lang=&edition=full","pubTime":"2022-12-19 12:09","market":"us","language":"en","title":"2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2292286774","media":"Motley Fool","summary":"These stocks look cheap -- especially considering their long-term potential.","content":"<html><head></head><body><p>You may see a lot of bargains in the shops and online this season. But there&#39;s an even better place to find a good deal these days. I&#39;m talking about the stock market. This year&#39;s long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.</p><p><i>&#34;But what if these stocks fall even further?&#34;</i> you might wonder. Well, it&#39;s impossible to effectively time the market, and it&#39;s a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you&#39;ll still benefit even if you didn&#39;t buy them at their cyclical low points.</p><p>If you&#39;re ready to give this winning strategy a try, here are two smart stocks I&#39;d recommend buying before the new year.</p><h2>1. Teladoc Health</h2><p><b>Teladoc Health</b> stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc&#39;s visits and revenue climbed by triple-digit percentages.</p><p>But the company has demonstrated it isn&#39;t a pandemic-only business. Teladoc&#39;s revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.</p><p>Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.</p><p>So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.</p><p>The third quarter brought investors some good news. Teladoc&#39;s loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.</p><p>Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it&#39;s expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.</p><p>Today, Teladoc shares are trading at their cheapest level <i>ever</i> in relation to sales. This is a major bargain considering the company&#39;s long-term potential.</p><h2>2. Abbott Laboratories</h2><p>There are two reasons to like <b>Abbott Laboratories</b>. First, let&#39;s talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it&#39;s particularly nice to have this guaranteed income during tough market times.</p><p>And Abbott isn&#39;t just a dividend stock -- it&#39;s a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.</p><p>Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.</p><p>Abbott has grown its free cash flow and return on invested capital over time.</p><p><img src=\"https://static.tigerbbs.com/053ae37cdf88229d770c12540a333184\" tg-width=\"720\" tg-height=\"463\" referrerpolicy=\"no-referrer\"/></p><p>ABT Free Cash Flow data by YCharts.</p><p>And it recently increased its full-year earnings-per-share forecast.</p><p>All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today&#39;s valuation of 20 times forward earnings estimates, Abbott&#39;s a stock you won&#39;t want to miss.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-19 12:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABT":"雅培","TDOC":"Teladoc Health Inc."},"source_url":"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2292286774","content_text":"You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.\"But what if these stocks fall even further?\" you might wonder. Well, it's impossible to effectively time the market, and it's a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you'll still benefit even if you didn't buy them at their cyclical low points.If you're ready to give this winning strategy a try, here are two smart stocks I'd recommend buying before the new year.1. Teladoc HealthTeladoc Health stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc's visits and revenue climbed by triple-digit percentages.But the company has demonstrated it isn't a pandemic-only business. Teladoc's revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.The third quarter brought investors some good news. Teladoc's loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it's expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.Today, Teladoc shares are trading at their cheapest level ever in relation to sales. This is a major bargain considering the company's long-term potential.2. Abbott LaboratoriesThere are two reasons to like Abbott Laboratories. First, let's talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it's particularly nice to have this guaranteed income during tough market times.And Abbott isn't just a dividend stock -- it's a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.Abbott has grown its free cash flow and return on invested capital over time.ABT Free Cash Flow data by YCharts.And it recently increased its full-year earnings-per-share forecast.All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today's valuation of 20 times forward earnings estimates, Abbott's a stock you won't want to miss.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9926072051,"gmtCreate":1671433210273,"gmtModify":1676538535587,"author":{"id":"3570852434754937","authorId":"3570852434754937","name":"Tbun","avatar":"https://community-static.tradeup.com/news/63e67729da4933c107a878402f4fce2c","vip":1,"crmLevel":7,"crmLevelSwitch":1},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9926072051","repostId":2292286774,"repostType":4,"repost":{"id":"2292286774","pubTimestamp":1671422971,"share":"https://www.laohu8.com/m/news/2292286774?lang=&edition=full","pubTime":"2022-12-19 12:09","market":"us","language":"en","title":"2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2292286774","media":"Motley Fool","summary":"These stocks look cheap -- especially considering their long-term potential.","content":"<html><head></head><body><p>You may see a lot of bargains in the shops and online this season. But there&#39;s an even better place to find a good deal these days. I&#39;m talking about the stock market. This year&#39;s long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.</p><p><i>&#34;But what if these stocks fall even further?&#34;</i> you might wonder. Well, it&#39;s impossible to effectively time the market, and it&#39;s a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you&#39;ll still benefit even if you didn&#39;t buy them at their cyclical low points.</p><p>If you&#39;re ready to give this winning strategy a try, here are two smart stocks I&#39;d recommend buying before the new year.</p><h2>1. Teladoc Health</h2><p><b>Teladoc Health</b> stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc&#39;s visits and revenue climbed by triple-digit percentages.</p><p>But the company has demonstrated it isn&#39;t a pandemic-only business. Teladoc&#39;s revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.</p><p>Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.</p><p>So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.</p><p>The third quarter brought investors some good news. Teladoc&#39;s loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.</p><p>Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it&#39;s expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.</p><p>Today, Teladoc shares are trading at their cheapest level <i>ever</i> in relation to sales. This is a major bargain considering the company&#39;s long-term potential.</p><h2>2. Abbott Laboratories</h2><p>There are two reasons to like <b>Abbott Laboratories</b>. First, let&#39;s talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it&#39;s particularly nice to have this guaranteed income during tough market times.</p><p>And Abbott isn&#39;t just a dividend stock -- it&#39;s a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.</p><p>Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.</p><p>Abbott has grown its free cash flow and return on invested capital over time.</p><p><img src=\"https://static.tigerbbs.com/053ae37cdf88229d770c12540a333184\" tg-width=\"720\" tg-height=\"463\" referrerpolicy=\"no-referrer\"/></p><p>ABT Free Cash Flow data by YCharts.</p><p>And it recently increased its full-year earnings-per-share forecast.</p><p>All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today&#39;s valuation of 20 times forward earnings estimates, Abbott&#39;s a stock you won&#39;t want to miss.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-19 12:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABT":"雅培","TDOC":"Teladoc Health Inc."},"source_url":"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2292286774","content_text":"You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.\"But what if these stocks fall even further?\" you might wonder. Well, it's impossible to effectively time the market, and it's a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you'll still benefit even if you didn't buy them at their cyclical low points.If you're ready to give this winning strategy a try, here are two smart stocks I'd recommend buying before the new year.1. Teladoc HealthTeladoc Health stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc's visits and revenue climbed by triple-digit percentages.But the company has demonstrated it isn't a pandemic-only business. Teladoc's revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.The third quarter brought investors some good news. Teladoc's loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it's expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.Today, Teladoc shares are trading at their cheapest level ever in relation to sales. This is a major bargain considering the company's long-term potential.2. Abbott LaboratoriesThere are two reasons to like Abbott Laboratories. First, let's talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it's particularly nice to have this guaranteed income during tough market times.And Abbott isn't just a dividend stock -- it's a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.Abbott has grown its free cash flow and return on invested capital over time.ABT Free Cash Flow data by YCharts.And it recently increased its full-year earnings-per-share forecast.All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today's valuation of 20 times forward earnings estimates, Abbott's a stock you won't want to miss.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9926076161,"gmtCreate":1671433023354,"gmtModify":1676538535563,"author":{"id":"4103274207793770","authorId":"4103274207793770","name":"JustLe","avatar":"https://community-static.tradeup.com/news/dfd907080cf16139ac249a71c37c435d","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9926076161","repostId":2292286774,"repostType":4,"repost":{"id":"2292286774","pubTimestamp":1671422971,"share":"https://www.laohu8.com/m/news/2292286774?lang=&edition=full","pubTime":"2022-12-19 12:09","market":"us","language":"en","title":"2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2292286774","media":"Motley Fool","summary":"These stocks look cheap -- especially considering their long-term potential.","content":"<html><head></head><body><p>You may see a lot of bargains in the shops and online this season. But there&#39;s an even better place to find a good deal these days. I&#39;m talking about the stock market. This year&#39;s long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.</p><p><i>&#34;But what if these stocks fall even further?&#34;</i> you might wonder. Well, it&#39;s impossible to effectively time the market, and it&#39;s a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you&#39;ll still benefit even if you didn&#39;t buy them at their cyclical low points.</p><p>If you&#39;re ready to give this winning strategy a try, here are two smart stocks I&#39;d recommend buying before the new year.</p><h2>1. Teladoc Health</h2><p><b>Teladoc Health</b> stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc&#39;s visits and revenue climbed by triple-digit percentages.</p><p>But the company has demonstrated it isn&#39;t a pandemic-only business. Teladoc&#39;s revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.</p><p>Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.</p><p>So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.</p><p>The third quarter brought investors some good news. Teladoc&#39;s loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.</p><p>Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it&#39;s expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.</p><p>Today, Teladoc shares are trading at their cheapest level <i>ever</i> in relation to sales. This is a major bargain considering the company&#39;s long-term potential.</p><h2>2. Abbott Laboratories</h2><p>There are two reasons to like <b>Abbott Laboratories</b>. First, let&#39;s talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it&#39;s particularly nice to have this guaranteed income during tough market times.</p><p>And Abbott isn&#39;t just a dividend stock -- it&#39;s a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.</p><p>Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.</p><p>Abbott has grown its free cash flow and return on invested capital over time.</p><p><img src=\"https://static.tigerbbs.com/053ae37cdf88229d770c12540a333184\" tg-width=\"720\" tg-height=\"463\" referrerpolicy=\"no-referrer\"/></p><p>ABT Free Cash Flow data by YCharts.</p><p>And it recently increased its full-year earnings-per-share forecast.</p><p>All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today&#39;s valuation of 20 times forward earnings estimates, Abbott&#39;s a stock you won&#39;t want to miss.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-19 12:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABT":"雅培","TDOC":"Teladoc Health Inc."},"source_url":"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2292286774","content_text":"You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.\"But what if these stocks fall even further?\" you might wonder. Well, it's impossible to effectively time the market, and it's a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you'll still benefit even if you didn't buy them at their cyclical low points.If you're ready to give this winning strategy a try, here are two smart stocks I'd recommend buying before the new year.1. Teladoc HealthTeladoc Health stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc's visits and revenue climbed by triple-digit percentages.But the company has demonstrated it isn't a pandemic-only business. Teladoc's revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.The third quarter brought investors some good news. Teladoc's loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it's expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.Today, Teladoc shares are trading at their cheapest level ever in relation to sales. This is a major bargain considering the company's long-term potential.2. Abbott LaboratoriesThere are two reasons to like Abbott Laboratories. First, let's talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it's particularly nice to have this guaranteed income during tough market times.And Abbott isn't just a dividend stock -- it's a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.Abbott has grown its free cash flow and return on invested capital over time.ABT Free Cash Flow data by YCharts.And it recently increased its full-year earnings-per-share forecast.All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today's valuation of 20 times forward earnings estimates, Abbott's a stock you won't want to miss.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":105260010,"gmtCreate":1671433030772,"gmtModify":1671433044100,"authorId":4103274207793770,"author":{"id":4103274207793770,"authorId":4103274207793770,"name":"JustLe","avatar":"https://community-static.tradeup.com/news/dfd907080cf16139ac249a71c37c435d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9926076161,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Ok</span>","text":"<span class=\"s1\">Ok</span>","html":"<span class=\"s1\">Ok</span>"}],"langContent":"EN"},{"id":9926049926,"gmtCreate":1671428360965,"gmtModify":1676538534975,"author":{"id":"3582969710070724","authorId":"3582969710070724","name":"OO_898","avatar":"https://static.tigerbbs.com/9fb3c360d5d7711641a868a144192fc7","vip":1,"crmLevel":4,"crmLevelSwitch":1},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9926049926","repostId":2292286774,"repostType":4,"repost":{"id":"2292286774","pubTimestamp":1671422971,"share":"https://www.laohu8.com/m/news/2292286774?lang=&edition=full","pubTime":"2022-12-19 12:09","market":"us","language":"en","title":"2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2292286774","media":"Motley Fool","summary":"These stocks look cheap -- especially considering their long-term potential.","content":"<html><head></head><body><p>You may see a lot of bargains in the shops and online this season. But there&#39;s an even better place to find a good deal these days. I&#39;m talking about the stock market. This year&#39;s long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.</p><p><i>&#34;But what if these stocks fall even further?&#34;</i> you might wonder. Well, it&#39;s impossible to effectively time the market, and it&#39;s a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you&#39;ll still benefit even if you didn&#39;t buy them at their cyclical low points.</p><p>If you&#39;re ready to give this winning strategy a try, here are two smart stocks I&#39;d recommend buying before the new year.</p><h2>1. Teladoc Health</h2><p><b>Teladoc Health</b> stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc&#39;s visits and revenue climbed by triple-digit percentages.</p><p>But the company has demonstrated it isn&#39;t a pandemic-only business. Teladoc&#39;s revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.</p><p>Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.</p><p>So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.</p><p>The third quarter brought investors some good news. Teladoc&#39;s loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.</p><p>Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it&#39;s expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.</p><p>Today, Teladoc shares are trading at their cheapest level <i>ever</i> in relation to sales. This is a major bargain considering the company&#39;s long-term potential.</p><h2>2. Abbott Laboratories</h2><p>There are two reasons to like <b>Abbott Laboratories</b>. First, let&#39;s talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it&#39;s particularly nice to have this guaranteed income during tough market times.</p><p>And Abbott isn&#39;t just a dividend stock -- it&#39;s a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.</p><p>Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.</p><p>Abbott has grown its free cash flow and return on invested capital over time.</p><p><img src=\"https://static.tigerbbs.com/053ae37cdf88229d770c12540a333184\" tg-width=\"720\" tg-height=\"463\" referrerpolicy=\"no-referrer\"/></p><p>ABT Free Cash Flow data by YCharts.</p><p>And it recently increased its full-year earnings-per-share forecast.</p><p>All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today&#39;s valuation of 20 times forward earnings estimates, Abbott&#39;s a stock you won&#39;t want to miss.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-19 12:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABT":"雅培","TDOC":"Teladoc Health Inc."},"source_url":"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2292286774","content_text":"You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.\"But what if these stocks fall even further?\" you might wonder. Well, it's impossible to effectively time the market, and it's a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you'll still benefit even if you didn't buy them at their cyclical low points.If you're ready to give this winning strategy a try, here are two smart stocks I'd recommend buying before the new year.1. Teladoc HealthTeladoc Health stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc's visits and revenue climbed by triple-digit percentages.But the company has demonstrated it isn't a pandemic-only business. Teladoc's revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.The third quarter brought investors some good news. Teladoc's loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it's expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.Today, Teladoc shares are trading at their cheapest level ever in relation to sales. This is a major bargain considering the company's long-term potential.2. Abbott LaboratoriesThere are two reasons to like Abbott Laboratories. First, let's talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it's particularly nice to have this guaranteed income during tough market times.And Abbott isn't just a dividend stock -- it's a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.Abbott has grown its free cash flow and return on invested capital over time.ABT Free Cash Flow data by YCharts.And it recently increased its full-year earnings-per-share forecast.All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today's valuation of 20 times forward earnings estimates, Abbott's a stock you won't want to miss.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9926040626,"gmtCreate":1671428262466,"gmtModify":1676538534950,"author":{"id":"3578819428738173","authorId":"3578819428738173","name":"EdwardKarchi","avatar":"https://static.tigerbbs.com/8393250f23521cbb5d95b0a87f3f846f","vip":1,"crmLevel":2,"crmLevelSwitch":1},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9926040626","repostId":2292286774,"repostType":4,"repost":{"id":"2292286774","pubTimestamp":1671422971,"share":"https://www.laohu8.com/m/news/2292286774?lang=&edition=full","pubTime":"2022-12-19 12:09","market":"us","language":"en","title":"2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2292286774","media":"Motley Fool","summary":"These stocks look cheap -- especially considering their long-term potential.","content":"<html><head></head><body><p>You may see a lot of bargains in the shops and online this season. But there&#39;s an even better place to find a good deal these days. I&#39;m talking about the stock market. This year&#39;s long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.</p><p><i>&#34;But what if these stocks fall even further?&#34;</i> you might wonder. Well, it&#39;s impossible to effectively time the market, and it&#39;s a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you&#39;ll still benefit even if you didn&#39;t buy them at their cyclical low points.</p><p>If you&#39;re ready to give this winning strategy a try, here are two smart stocks I&#39;d recommend buying before the new year.</p><h2>1. Teladoc Health</h2><p><b>Teladoc Health</b> stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc&#39;s visits and revenue climbed by triple-digit percentages.</p><p>But the company has demonstrated it isn&#39;t a pandemic-only business. Teladoc&#39;s revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.</p><p>Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.</p><p>So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.</p><p>The third quarter brought investors some good news. Teladoc&#39;s loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.</p><p>Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it&#39;s expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.</p><p>Today, Teladoc shares are trading at their cheapest level <i>ever</i> in relation to sales. This is a major bargain considering the company&#39;s long-term potential.</p><h2>2. Abbott Laboratories</h2><p>There are two reasons to like <b>Abbott Laboratories</b>. First, let&#39;s talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it&#39;s particularly nice to have this guaranteed income during tough market times.</p><p>And Abbott isn&#39;t just a dividend stock -- it&#39;s a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.</p><p>Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.</p><p>Abbott has grown its free cash flow and return on invested capital over time.</p><p><img src=\"https://static.tigerbbs.com/053ae37cdf88229d770c12540a333184\" tg-width=\"720\" tg-height=\"463\" referrerpolicy=\"no-referrer\"/></p><p>ABT Free Cash Flow data by YCharts.</p><p>And it recently increased its full-year earnings-per-share forecast.</p><p>All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today&#39;s valuation of 20 times forward earnings estimates, Abbott&#39;s a stock you won&#39;t want to miss.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-19 12:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABT":"雅培","TDOC":"Teladoc Health Inc."},"source_url":"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2292286774","content_text":"You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.\"But what if these stocks fall even further?\" you might wonder. Well, it's impossible to effectively time the market, and it's a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you'll still benefit even if you didn't buy them at their cyclical low points.If you're ready to give this winning strategy a try, here are two smart stocks I'd recommend buying before the new year.1. Teladoc HealthTeladoc Health stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc's visits and revenue climbed by triple-digit percentages.But the company has demonstrated it isn't a pandemic-only business. Teladoc's revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.The third quarter brought investors some good news. Teladoc's loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it's expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.Today, Teladoc shares are trading at their cheapest level ever in relation to sales. This is a major bargain considering the company's long-term potential.2. Abbott LaboratoriesThere are two reasons to like Abbott Laboratories. First, let's talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it's particularly nice to have this guaranteed income during tough market times.And Abbott isn't just a dividend stock -- it's a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.Abbott has grown its free cash flow and return on invested capital over time.ABT Free Cash Flow data by YCharts.And it recently increased its full-year earnings-per-share forecast.All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today's valuation of 20 times forward earnings estimates, Abbott's a stock you won't want to miss.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9926055504,"gmtCreate":1671427520808,"gmtModify":1676538534829,"author":{"id":"3578382329083125","authorId":"3578382329083125","name":"Hayleyxn","avatar":"https://static.tigerbbs.com/38f91d6f48b5ef2c23595e416b33bb59","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"OK","listText":"OK","text":"OK","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9926055504","repostId":2292286774,"repostType":4,"repost":{"id":"2292286774","pubTimestamp":1671422971,"share":"https://www.laohu8.com/m/news/2292286774?lang=&edition=full","pubTime":"2022-12-19 12:09","market":"us","language":"en","title":"2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2292286774","media":"Motley Fool","summary":"These stocks look cheap -- especially considering their long-term potential.","content":"<html><head></head><body><p>You may see a lot of bargains in the shops and online this season. But there&#39;s an even better place to find a good deal these days. I&#39;m talking about the stock market. This year&#39;s long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.</p><p><i>&#34;But what if these stocks fall even further?&#34;</i> you might wonder. Well, it&#39;s impossible to effectively time the market, and it&#39;s a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you&#39;ll still benefit even if you didn&#39;t buy them at their cyclical low points.</p><p>If you&#39;re ready to give this winning strategy a try, here are two smart stocks I&#39;d recommend buying before the new year.</p><h2>1. Teladoc Health</h2><p><b>Teladoc Health</b> stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc&#39;s visits and revenue climbed by triple-digit percentages.</p><p>But the company has demonstrated it isn&#39;t a pandemic-only business. Teladoc&#39;s revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.</p><p>Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.</p><p>So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.</p><p>The third quarter brought investors some good news. Teladoc&#39;s loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.</p><p>Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it&#39;s expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.</p><p>Today, Teladoc shares are trading at their cheapest level <i>ever</i> in relation to sales. This is a major bargain considering the company&#39;s long-term potential.</p><h2>2. Abbott Laboratories</h2><p>There are two reasons to like <b>Abbott Laboratories</b>. First, let&#39;s talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it&#39;s particularly nice to have this guaranteed income during tough market times.</p><p>And Abbott isn&#39;t just a dividend stock -- it&#39;s a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.</p><p>Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.</p><p>Abbott has grown its free cash flow and return on invested capital over time.</p><p><img src=\"https://static.tigerbbs.com/053ae37cdf88229d770c12540a333184\" tg-width=\"720\" tg-height=\"463\" referrerpolicy=\"no-referrer\"/></p><p>ABT Free Cash Flow data by YCharts.</p><p>And it recently increased its full-year earnings-per-share forecast.</p><p>All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today&#39;s valuation of 20 times forward earnings estimates, Abbott&#39;s a stock you won&#39;t want to miss.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-19 12:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABT":"雅培","TDOC":"Teladoc Health Inc."},"source_url":"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2292286774","content_text":"You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.\"But what if these stocks fall even further?\" you might wonder. Well, it's impossible to effectively time the market, and it's a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you'll still benefit even if you didn't buy them at their cyclical low points.If you're ready to give this winning strategy a try, here are two smart stocks I'd recommend buying before the new year.1. Teladoc HealthTeladoc Health stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc's visits and revenue climbed by triple-digit percentages.But the company has demonstrated it isn't a pandemic-only business. Teladoc's revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.The third quarter brought investors some good news. Teladoc's loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it's expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.Today, Teladoc shares are trading at their cheapest level ever in relation to sales. This is a major bargain considering the company's long-term potential.2. Abbott LaboratoriesThere are two reasons to like Abbott Laboratories. First, let's talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it's particularly nice to have this guaranteed income during tough market times.And Abbott isn't just a dividend stock -- it's a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.Abbott has grown its free cash flow and return on invested capital over time.ABT Free Cash Flow data by YCharts.And it recently increased its full-year earnings-per-share forecast.All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today's valuation of 20 times forward earnings estimates, Abbott's a stock you won't want to miss.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":105259194,"gmtCreate":1671428278437,"gmtModify":1671428291673,"authorId":3578819428738173,"author":{"id":3578819428738173,"authorId":3578819428738173,"name":"EdwardKarchi","avatar":"https://static.tigerbbs.com/8393250f23521cbb5d95b0a87f3f846f","vip":1,"currentWearingBadge":{"badgeId":"f00de38e20574ad1abf55a15966547c8-1","templateUuid":"f00de38e20574ad1abf55a15966547c8","name":"Average winning trade","description":"Top 50%","bigImgUrl":"https://community-static.tradeup.com/news/f53cdecfbff6499d133bad354ae10ff1","smallImgUrl":"https://community-static.tradeup.com/news/2554f84686bbcccc035b93fe29308e43","grayImgUrl":"https://community-static.tradeup.com/news/84c66bc70ac1cf09f4e89b1d4ca9d017","redirectLinkEnabled":1,"redirectLink":"https://www.tigerbrokers.com.sg/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.04.19","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":5200},"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9926055504,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Ok</span>","text":"<span class=\"s1\">Ok</span>","html":"<span class=\"s1\">Ok</span>"},{"id":105259080,"gmtCreate":1671427526450,"gmtModify":1671427539629,"authorId":3578382329083125,"author":{"id":3578382329083125,"authorId":3578382329083125,"name":"Hayleyxn","avatar":"https://static.tigerbbs.com/38f91d6f48b5ef2c23595e416b33bb59","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9926055504,"type":1,"supId":0,"prevId":0,"content":"OK","text":"OK","html":"OK"}],"langContent":"EN"},{"id":9926058131,"gmtCreate":1671426880223,"gmtModify":1676538534649,"author":{"id":"4116119002753472","authorId":"4116119002753472","name":"MickeyBond","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":1},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9926058131","repostId":2292286774,"repostType":4,"repost":{"id":"2292286774","pubTimestamp":1671422971,"share":"https://www.laohu8.com/m/news/2292286774?lang=&edition=full","pubTime":"2022-12-19 12:09","market":"us","language":"en","title":"2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2292286774","media":"Motley Fool","summary":"These stocks look cheap -- especially considering their long-term potential.","content":"<html><head></head><body><p>You may see a lot of bargains in the shops and online this season. But there&#39;s an even better place to find a good deal these days. I&#39;m talking about the stock market. This year&#39;s long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.</p><p><i>&#34;But what if these stocks fall even further?&#34;</i> you might wonder. Well, it&#39;s impossible to effectively time the market, and it&#39;s a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you&#39;ll still benefit even if you didn&#39;t buy them at their cyclical low points.</p><p>If you&#39;re ready to give this winning strategy a try, here are two smart stocks I&#39;d recommend buying before the new year.</p><h2>1. Teladoc Health</h2><p><b>Teladoc Health</b> stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc&#39;s visits and revenue climbed by triple-digit percentages.</p><p>But the company has demonstrated it isn&#39;t a pandemic-only business. Teladoc&#39;s revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.</p><p>Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.</p><p>So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.</p><p>The third quarter brought investors some good news. Teladoc&#39;s loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.</p><p>Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it&#39;s expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.</p><p>Today, Teladoc shares are trading at their cheapest level <i>ever</i> in relation to sales. This is a major bargain considering the company&#39;s long-term potential.</p><h2>2. Abbott Laboratories</h2><p>There are two reasons to like <b>Abbott Laboratories</b>. First, let&#39;s talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it&#39;s particularly nice to have this guaranteed income during tough market times.</p><p>And Abbott isn&#39;t just a dividend stock -- it&#39;s a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.</p><p>Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.</p><p>Abbott has grown its free cash flow and return on invested capital over time.</p><p><img src=\"https://static.tigerbbs.com/053ae37cdf88229d770c12540a333184\" tg-width=\"720\" tg-height=\"463\" referrerpolicy=\"no-referrer\"/></p><p>ABT Free Cash Flow data by YCharts.</p><p>And it recently increased its full-year earnings-per-share forecast.</p><p>All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today&#39;s valuation of 20 times forward earnings estimates, Abbott&#39;s a stock you won&#39;t want to miss.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-19 12:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABT":"雅培","TDOC":"Teladoc Health Inc."},"source_url":"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2292286774","content_text":"You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.\"But what if these stocks fall even further?\" you might wonder. Well, it's impossible to effectively time the market, and it's a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you'll still benefit even if you didn't buy them at their cyclical low points.If you're ready to give this winning strategy a try, here are two smart stocks I'd recommend buying before the new year.1. Teladoc HealthTeladoc Health stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc's visits and revenue climbed by triple-digit percentages.But the company has demonstrated it isn't a pandemic-only business. Teladoc's revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.The third quarter brought investors some good news. Teladoc's loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it's expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.Today, Teladoc shares are trading at their cheapest level ever in relation to sales. This is a major bargain considering the company's long-term potential.2. Abbott LaboratoriesThere are two reasons to like Abbott Laboratories. First, let's talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it's particularly nice to have this guaranteed income during tough market times.And Abbott isn't just a dividend stock -- it's a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.Abbott has grown its free cash flow and return on invested capital over time.ABT Free Cash Flow data by YCharts.And it recently increased its full-year earnings-per-share forecast.All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today's valuation of 20 times forward earnings estimates, Abbott's a stock you won't want to miss.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9926051692,"gmtCreate":1671426713817,"gmtModify":1676538534625,"author":{"id":"3555200317437246","authorId":"3555200317437246","name":"weekendnote","avatar":"https://community-static.tradeup.com/news/d60a8ac425f5151e5bcdc426262fb043","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ok&nbsp;","listText":"Ok&nbsp;","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9926051692","repostId":2292286774,"repostType":4,"repost":{"id":"2292286774","pubTimestamp":1671422971,"share":"https://www.laohu8.com/m/news/2292286774?lang=&edition=full","pubTime":"2022-12-19 12:09","market":"us","language":"en","title":"2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2292286774","media":"Motley Fool","summary":"These stocks look cheap -- especially considering their long-term potential.","content":"<html><head></head><body><p>You may see a lot of bargains in the shops and online this season. But there&#39;s an even better place to find a good deal these days. I&#39;m talking about the stock market. This year&#39;s long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.</p><p><i>&#34;But what if these stocks fall even further?&#34;</i> you might wonder. Well, it&#39;s impossible to effectively time the market, and it&#39;s a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you&#39;ll still benefit even if you didn&#39;t buy them at their cyclical low points.</p><p>If you&#39;re ready to give this winning strategy a try, here are two smart stocks I&#39;d recommend buying before the new year.</p><h2>1. Teladoc Health</h2><p><b>Teladoc Health</b> stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc&#39;s visits and revenue climbed by triple-digit percentages.</p><p>But the company has demonstrated it isn&#39;t a pandemic-only business. Teladoc&#39;s revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.</p><p>Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.</p><p>So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.</p><p>The third quarter brought investors some good news. Teladoc&#39;s loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.</p><p>Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it&#39;s expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.</p><p>Today, Teladoc shares are trading at their cheapest level <i>ever</i> in relation to sales. This is a major bargain considering the company&#39;s long-term potential.</p><h2>2. Abbott Laboratories</h2><p>There are two reasons to like <b>Abbott Laboratories</b>. First, let&#39;s talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it&#39;s particularly nice to have this guaranteed income during tough market times.</p><p>And Abbott isn&#39;t just a dividend stock -- it&#39;s a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.</p><p>Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.</p><p>Abbott has grown its free cash flow and return on invested capital over time.</p><p><img src=\"https://static.tigerbbs.com/053ae37cdf88229d770c12540a333184\" tg-width=\"720\" tg-height=\"463\" referrerpolicy=\"no-referrer\"/></p><p>ABT Free Cash Flow data by YCharts.</p><p>And it recently increased its full-year earnings-per-share forecast.</p><p>All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today&#39;s valuation of 20 times forward earnings estimates, Abbott&#39;s a stock you won&#39;t want to miss.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-19 12:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABT":"雅培","TDOC":"Teladoc Health Inc."},"source_url":"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2292286774","content_text":"You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.\"But what if these stocks fall even further?\" you might wonder. Well, it's impossible to effectively time the market, and it's a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you'll still benefit even if you didn't buy them at their cyclical low points.If you're ready to give this winning strategy a try, here are two smart stocks I'd recommend buying before the new year.1. Teladoc HealthTeladoc Health stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc's visits and revenue climbed by triple-digit percentages.But the company has demonstrated it isn't a pandemic-only business. Teladoc's revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.The third quarter brought investors some good news. Teladoc's loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it's expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.Today, Teladoc shares are trading at their cheapest level ever in relation to sales. This is a major bargain considering the company's long-term potential.2. Abbott LaboratoriesThere are two reasons to like Abbott Laboratories. First, let's talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it's particularly nice to have this guaranteed income during tough market times.And Abbott isn't just a dividend stock -- it's a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.Abbott has grown its free cash flow and return on invested capital over time.ABT Free Cash Flow data by YCharts.And it recently increased its full-year earnings-per-share forecast.All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today's valuation of 20 times forward earnings estimates, Abbott's a stock you won't want to miss.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9926053099,"gmtCreate":1671426497212,"gmtModify":1676538534584,"author":{"id":"3577323914202336","authorId":"3577323914202336","name":"V K","avatar":"https://static.tigerbbs.com/536d624e5750dcffec704eeed9bc003b","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":5,"crmLevelSwitch":1},"htmlText":"Pls like tyvm[Happy]&nbsp;","listText":"Pls like tyvm[Happy]&nbsp;","text":"Pls like tyvm[Happy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9926053099","repostId":2292286774,"repostType":4,"repost":{"id":"2292286774","pubTimestamp":1671422971,"share":"https://www.laohu8.com/m/news/2292286774?lang=&edition=full","pubTime":"2022-12-19 12:09","market":"us","language":"en","title":"2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2292286774","media":"Motley Fool","summary":"These stocks look cheap -- especially considering their long-term potential.","content":"<html><head></head><body><p>You may see a lot of bargains in the shops and online this season. But there&#39;s an even better place to find a good deal these days. I&#39;m talking about the stock market. This year&#39;s long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.</p><p><i>&#34;But what if these stocks fall even further?&#34;</i> you might wonder. Well, it&#39;s impossible to effectively time the market, and it&#39;s a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you&#39;ll still benefit even if you didn&#39;t buy them at their cyclical low points.</p><p>If you&#39;re ready to give this winning strategy a try, here are two smart stocks I&#39;d recommend buying before the new year.</p><h2>1. Teladoc Health</h2><p><b>Teladoc Health</b> stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc&#39;s visits and revenue climbed by triple-digit percentages.</p><p>But the company has demonstrated it isn&#39;t a pandemic-only business. Teladoc&#39;s revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.</p><p>Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.</p><p>So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.</p><p>The third quarter brought investors some good news. Teladoc&#39;s loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.</p><p>Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it&#39;s expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.</p><p>Today, Teladoc shares are trading at their cheapest level <i>ever</i> in relation to sales. This is a major bargain considering the company&#39;s long-term potential.</p><h2>2. Abbott Laboratories</h2><p>There are two reasons to like <b>Abbott Laboratories</b>. First, let&#39;s talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it&#39;s particularly nice to have this guaranteed income during tough market times.</p><p>And Abbott isn&#39;t just a dividend stock -- it&#39;s a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.</p><p>Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.</p><p>Abbott has grown its free cash flow and return on invested capital over time.</p><p><img src=\"https://static.tigerbbs.com/053ae37cdf88229d770c12540a333184\" tg-width=\"720\" tg-height=\"463\" referrerpolicy=\"no-referrer\"/></p><p>ABT Free Cash Flow data by YCharts.</p><p>And it recently increased its full-year earnings-per-share forecast.</p><p>All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today&#39;s valuation of 20 times forward earnings estimates, Abbott&#39;s a stock you won&#39;t want to miss.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-19 12:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABT":"雅培","TDOC":"Teladoc Health Inc."},"source_url":"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2292286774","content_text":"You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.\"But what if these stocks fall even further?\" you might wonder. Well, it's impossible to effectively time the market, and it's a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you'll still benefit even if you didn't buy them at their cyclical low points.If you're ready to give this winning strategy a try, here are two smart stocks I'd recommend buying before the new year.1. Teladoc HealthTeladoc Health stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc's visits and revenue climbed by triple-digit percentages.But the company has demonstrated it isn't a pandemic-only business. Teladoc's revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.The third quarter brought investors some good news. Teladoc's loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it's expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.Today, Teladoc shares are trading at their cheapest level ever in relation to sales. This is a major bargain considering the company's long-term potential.2. Abbott LaboratoriesThere are two reasons to like Abbott Laboratories. First, let's talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it's particularly nice to have this guaranteed income during tough market times.And Abbott isn't just a dividend stock -- it's a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.Abbott has grown its free cash flow and return on invested capital over time.ABT Free Cash Flow data by YCharts.And it recently increased its full-year earnings-per-share forecast.All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today's valuation of 20 times forward earnings estimates, Abbott's a stock you won't want to miss.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9926059068,"gmtCreate":1671426277054,"gmtModify":1676538534555,"author":{"id":"3558617926022722","authorId":"3558617926022722","name":"kkennn","avatar":"https://static.tigerbbs.com/cfb6967409b5a69e663a7006e885e221","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Upp","listText":"Upp","text":"Upp","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9926059068","repostId":2292286774,"repostType":4,"repost":{"id":"2292286774","pubTimestamp":1671422971,"share":"https://www.laohu8.com/m/news/2292286774?lang=&edition=full","pubTime":"2022-12-19 12:09","market":"us","language":"en","title":"2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2292286774","media":"Motley Fool","summary":"These stocks look cheap -- especially considering their long-term potential.","content":"<html><head></head><body><p>You may see a lot of bargains in the shops and online this season. But there&#39;s an even better place to find a good deal these days. I&#39;m talking about the stock market. This year&#39;s long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.</p><p><i>&#34;But what if these stocks fall even further?&#34;</i> you might wonder. Well, it&#39;s impossible to effectively time the market, and it&#39;s a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you&#39;ll still benefit even if you didn&#39;t buy them at their cyclical low points.</p><p>If you&#39;re ready to give this winning strategy a try, here are two smart stocks I&#39;d recommend buying before the new year.</p><h2>1. Teladoc Health</h2><p><b>Teladoc Health</b> stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc&#39;s visits and revenue climbed by triple-digit percentages.</p><p>But the company has demonstrated it isn&#39;t a pandemic-only business. Teladoc&#39;s revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.</p><p>Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.</p><p>So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.</p><p>The third quarter brought investors some good news. Teladoc&#39;s loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.</p><p>Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it&#39;s expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.</p><p>Today, Teladoc shares are trading at their cheapest level <i>ever</i> in relation to sales. This is a major bargain considering the company&#39;s long-term potential.</p><h2>2. Abbott Laboratories</h2><p>There are two reasons to like <b>Abbott Laboratories</b>. First, let&#39;s talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it&#39;s particularly nice to have this guaranteed income during tough market times.</p><p>And Abbott isn&#39;t just a dividend stock -- it&#39;s a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.</p><p>Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.</p><p>Abbott has grown its free cash flow and return on invested capital over time.</p><p><img src=\"https://static.tigerbbs.com/053ae37cdf88229d770c12540a333184\" tg-width=\"720\" tg-height=\"463\" referrerpolicy=\"no-referrer\"/></p><p>ABT Free Cash Flow data by YCharts.</p><p>And it recently increased its full-year earnings-per-share forecast.</p><p>All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today&#39;s valuation of 20 times forward earnings estimates, Abbott&#39;s a stock you won&#39;t want to miss.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-19 12:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABT":"雅培","TDOC":"Teladoc Health Inc."},"source_url":"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2292286774","content_text":"You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.\"But what if these stocks fall even further?\" you might wonder. Well, it's impossible to effectively time the market, and it's a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you'll still benefit even if you didn't buy them at their cyclical low points.If you're ready to give this winning strategy a try, here are two smart stocks I'd recommend buying before the new year.1. Teladoc HealthTeladoc Health stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc's visits and revenue climbed by triple-digit percentages.But the company has demonstrated it isn't a pandemic-only business. Teladoc's revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.The third quarter brought investors some good news. Teladoc's loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it's expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.Today, Teladoc shares are trading at their cheapest level ever in relation to sales. This is a major bargain considering the company's long-term potential.2. Abbott LaboratoriesThere are two reasons to like Abbott Laboratories. First, let's talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it's particularly nice to have this guaranteed income during tough market times.And Abbott isn't just a dividend stock -- it's a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.Abbott has grown its free cash flow and return on invested capital over time.ABT Free Cash Flow data by YCharts.And it recently increased its full-year earnings-per-share forecast.All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today's valuation of 20 times forward earnings estimates, Abbott's a stock you won't want to miss.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":105258889,"gmtCreate":1671426346105,"gmtModify":1671426356061,"authorId":3569282887853056,"author":{"id":3569282887853056,"authorId":3569282887853056,"name":"Princessleo","avatar":"https://community-static.tradeup.com/news/1145a6f471e451b1b446022e0eaed860","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9926059068,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Yo</span>","text":"<span class=\"s1\">Yo</span>","html":"<span class=\"s1\">Yo</span>"}],"langContent":"EN"},{"id":9926024236,"gmtCreate":1671425784125,"gmtModify":1676538534421,"author":{"id":"3581250600180292","authorId":"3581250600180292","name":"TTM Investor","avatar":"https://community-static.tradeup.com/news/2f5fd716e63ae3848b455b2214a559df","vip":1,"crmLevel":6,"crmLevelSwitch":1},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9926024236","repostId":2292286774,"repostType":4,"repost":{"id":"2292286774","pubTimestamp":1671422971,"share":"https://www.laohu8.com/m/news/2292286774?lang=&edition=full","pubTime":"2022-12-19 12:09","market":"us","language":"en","title":"2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2292286774","media":"Motley Fool","summary":"These stocks look cheap -- especially considering their long-term potential.","content":"<html><head></head><body><p>You may see a lot of bargains in the shops and online this season. But there&#39;s an even better place to find a good deal these days. I&#39;m talking about the stock market. This year&#39;s long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.</p><p><i>&#34;But what if these stocks fall even further?&#34;</i> you might wonder. Well, it&#39;s impossible to effectively time the market, and it&#39;s a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you&#39;ll still benefit even if you didn&#39;t buy them at their cyclical low points.</p><p>If you&#39;re ready to give this winning strategy a try, here are two smart stocks I&#39;d recommend buying before the new year.</p><h2>1. Teladoc Health</h2><p><b>Teladoc Health</b> stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc&#39;s visits and revenue climbed by triple-digit percentages.</p><p>But the company has demonstrated it isn&#39;t a pandemic-only business. Teladoc&#39;s revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.</p><p>Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.</p><p>So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.</p><p>The third quarter brought investors some good news. Teladoc&#39;s loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.</p><p>Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it&#39;s expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.</p><p>Today, Teladoc shares are trading at their cheapest level <i>ever</i> in relation to sales. This is a major bargain considering the company&#39;s long-term potential.</p><h2>2. Abbott Laboratories</h2><p>There are two reasons to like <b>Abbott Laboratories</b>. First, let&#39;s talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it&#39;s particularly nice to have this guaranteed income during tough market times.</p><p>And Abbott isn&#39;t just a dividend stock -- it&#39;s a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.</p><p>Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.</p><p>Abbott has grown its free cash flow and return on invested capital over time.</p><p><img src=\"https://static.tigerbbs.com/053ae37cdf88229d770c12540a333184\" tg-width=\"720\" tg-height=\"463\" referrerpolicy=\"no-referrer\"/></p><p>ABT Free Cash Flow data by YCharts.</p><p>And it recently increased its full-year earnings-per-share forecast.</p><p>All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today&#39;s valuation of 20 times forward earnings estimates, Abbott&#39;s a stock you won&#39;t want to miss.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-19 12:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABT":"雅培","TDOC":"Teladoc Health Inc."},"source_url":"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2292286774","content_text":"You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.\"But what if these stocks fall even further?\" you might wonder. Well, it's impossible to effectively time the market, and it's a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you'll still benefit even if you didn't buy them at their cyclical low points.If you're ready to give this winning strategy a try, here are two smart stocks I'd recommend buying before the new year.1. Teladoc HealthTeladoc Health stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc's visits and revenue climbed by triple-digit percentages.But the company has demonstrated it isn't a pandemic-only business. Teladoc's revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.The third quarter brought investors some good news. Teladoc's loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it's expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.Today, Teladoc shares are trading at their cheapest level ever in relation to sales. This is a major bargain considering the company's long-term potential.2. Abbott LaboratoriesThere are two reasons to like Abbott Laboratories. First, let's talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it's particularly nice to have this guaranteed income during tough market times.And Abbott isn't just a dividend stock -- it's a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.Abbott has grown its free cash flow and return on invested capital over time.ABT Free Cash Flow data by YCharts.And it recently increased its full-year earnings-per-share forecast.All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today's valuation of 20 times forward earnings estimates, Abbott's a stock you won't want to miss.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9926022428,"gmtCreate":1671425370465,"gmtModify":1676538534375,"author":{"id":"3571083769580822","authorId":"3571083769580822","name":"YsL","avatar":"https://static.tigerbbs.com/f258b1aa573da15fd74641181f7391bf","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9926022428","repostId":2292286774,"repostType":4,"repost":{"id":"2292286774","pubTimestamp":1671422971,"share":"https://www.laohu8.com/m/news/2292286774?lang=&edition=full","pubTime":"2022-12-19 12:09","market":"us","language":"en","title":"2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2292286774","media":"Motley Fool","summary":"These stocks look cheap -- especially considering their long-term potential.","content":"<html><head></head><body><p>You may see a lot of bargains in the shops and online this season. But there&#39;s an even better place to find a good deal these days. I&#39;m talking about the stock market. This year&#39;s long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.</p><p><i>&#34;But what if these stocks fall even further?&#34;</i> you might wonder. Well, it&#39;s impossible to effectively time the market, and it&#39;s a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you&#39;ll still benefit even if you didn&#39;t buy them at their cyclical low points.</p><p>If you&#39;re ready to give this winning strategy a try, here are two smart stocks I&#39;d recommend buying before the new year.</p><h2>1. Teladoc Health</h2><p><b>Teladoc Health</b> stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc&#39;s visits and revenue climbed by triple-digit percentages.</p><p>But the company has demonstrated it isn&#39;t a pandemic-only business. Teladoc&#39;s revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.</p><p>Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.</p><p>So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.</p><p>The third quarter brought investors some good news. Teladoc&#39;s loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.</p><p>Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it&#39;s expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.</p><p>Today, Teladoc shares are trading at their cheapest level <i>ever</i> in relation to sales. This is a major bargain considering the company&#39;s long-term potential.</p><h2>2. Abbott Laboratories</h2><p>There are two reasons to like <b>Abbott Laboratories</b>. First, let&#39;s talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it&#39;s particularly nice to have this guaranteed income during tough market times.</p><p>And Abbott isn&#39;t just a dividend stock -- it&#39;s a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.</p><p>Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.</p><p>Abbott has grown its free cash flow and return on invested capital over time.</p><p><img src=\"https://static.tigerbbs.com/053ae37cdf88229d770c12540a333184\" tg-width=\"720\" tg-height=\"463\" referrerpolicy=\"no-referrer\"/></p><p>ABT Free Cash Flow data by YCharts.</p><p>And it recently increased its full-year earnings-per-share forecast.</p><p>All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today&#39;s valuation of 20 times forward earnings estimates, Abbott&#39;s a stock you won&#39;t want to miss.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-19 12:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABT":"雅培","TDOC":"Teladoc Health Inc."},"source_url":"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2292286774","content_text":"You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.\"But what if these stocks fall even further?\" you might wonder. Well, it's impossible to effectively time the market, and it's a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you'll still benefit even if you didn't buy them at their cyclical low points.If you're ready to give this winning strategy a try, here are two smart stocks I'd recommend buying before the new year.1. Teladoc HealthTeladoc Health stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc's visits and revenue climbed by triple-digit percentages.But the company has demonstrated it isn't a pandemic-only business. Teladoc's revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.The third quarter brought investors some good news. Teladoc's loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it's expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.Today, Teladoc shares are trading at their cheapest level ever in relation to sales. This is a major bargain considering the company's long-term potential.2. Abbott LaboratoriesThere are two reasons to like Abbott Laboratories. First, let's talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it's particularly nice to have this guaranteed income during tough market times.And Abbott isn't just a dividend stock -- it's a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.Abbott has grown its free cash flow and return on invested capital over time.ABT Free Cash Flow data by YCharts.And it recently increased its full-year earnings-per-share forecast.All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today's valuation of 20 times forward earnings estimates, Abbott's a stock you won't want to miss.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9926026403,"gmtCreate":1671425067603,"gmtModify":1676538534335,"author":{"id":"3581989576547489","authorId":"3581989576547489","name":"SimonTan91","avatar":"https://static.tigerbbs.com/33a746662324e75f8c65f010f1588b16","vip":1,"crmLevel":7,"crmLevelSwitch":0},"htmlText":"Oo","listText":"Oo","text":"Oo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9926026403","repostId":2292286774,"repostType":4,"repost":{"id":"2292286774","pubTimestamp":1671422971,"share":"https://www.laohu8.com/m/news/2292286774?lang=&edition=full","pubTime":"2022-12-19 12:09","market":"us","language":"en","title":"2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2292286774","media":"Motley Fool","summary":"These stocks look cheap -- especially considering their long-term potential.","content":"<html><head></head><body><p>You may see a lot of bargains in the shops and online this season. But there&#39;s an even better place to find a good deal these days. I&#39;m talking about the stock market. This year&#39;s long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.</p><p><i>&#34;But what if these stocks fall even further?&#34;</i> you might wonder. Well, it&#39;s impossible to effectively time the market, and it&#39;s a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you&#39;ll still benefit even if you didn&#39;t buy them at their cyclical low points.</p><p>If you&#39;re ready to give this winning strategy a try, here are two smart stocks I&#39;d recommend buying before the new year.</p><h2>1. Teladoc Health</h2><p><b>Teladoc Health</b> stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc&#39;s visits and revenue climbed by triple-digit percentages.</p><p>But the company has demonstrated it isn&#39;t a pandemic-only business. Teladoc&#39;s revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.</p><p>Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.</p><p>So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.</p><p>The third quarter brought investors some good news. Teladoc&#39;s loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.</p><p>Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it&#39;s expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.</p><p>Today, Teladoc shares are trading at their cheapest level <i>ever</i> in relation to sales. This is a major bargain considering the company&#39;s long-term potential.</p><h2>2. Abbott Laboratories</h2><p>There are two reasons to like <b>Abbott Laboratories</b>. First, let&#39;s talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it&#39;s particularly nice to have this guaranteed income during tough market times.</p><p>And Abbott isn&#39;t just a dividend stock -- it&#39;s a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.</p><p>Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.</p><p>Abbott has grown its free cash flow and return on invested capital over time.</p><p><img src=\"https://static.tigerbbs.com/053ae37cdf88229d770c12540a333184\" tg-width=\"720\" tg-height=\"463\" referrerpolicy=\"no-referrer\"/></p><p>ABT Free Cash Flow data by YCharts.</p><p>And it recently increased its full-year earnings-per-share forecast.</p><p>All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today&#39;s valuation of 20 times forward earnings estimates, Abbott&#39;s a stock you won&#39;t want to miss.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-19 12:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABT":"雅培","TDOC":"Teladoc Health Inc."},"source_url":"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2292286774","content_text":"You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.\"But what if these stocks fall even further?\" you might wonder. Well, it's impossible to effectively time the market, and it's a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you'll still benefit even if you didn't buy them at their cyclical low points.If you're ready to give this winning strategy a try, here are two smart stocks I'd recommend buying before the new year.1. Teladoc HealthTeladoc Health stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc's visits and revenue climbed by triple-digit percentages.But the company has demonstrated it isn't a pandemic-only business. Teladoc's revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.The third quarter brought investors some good news. Teladoc's loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it's expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.Today, Teladoc shares are trading at their cheapest level ever in relation to sales. This is a major bargain considering the company's long-term potential.2. Abbott LaboratoriesThere are two reasons to like Abbott Laboratories. First, let's talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it's particularly nice to have this guaranteed income during tough market times.And Abbott isn't just a dividend stock -- it's a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.Abbott has grown its free cash flow and return on invested capital over time.ABT Free Cash Flow data by YCharts.And it recently increased its full-year earnings-per-share forecast.All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today's valuation of 20 times forward earnings estimates, Abbott's a stock you won't want to miss.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":105258884,"gmtCreate":1671426284713,"gmtModify":1671426297636,"authorId":3558617926022722,"author":{"id":3558617926022722,"authorId":3558617926022722,"name":"kkennn","avatar":"https://static.tigerbbs.com/cfb6967409b5a69e663a7006e885e221","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9926026403,"type":1,"supId":0,"prevId":0,"content":"<u>Ok</u>","text":"<u>Ok</u>","html":"<u>Ok</u>"}],"langContent":"EN"},{"id":9926021180,"gmtCreate":1671424249240,"gmtModify":1676538534256,"author":{"id":"4089777453696550","authorId":"4089777453696550","name":"soosoo","avatar":"https://static.tigerbbs.com/a7a8e4a0c1e8d4b7bf1e9db91cfaffc8","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9926021180","repostId":2292286774,"repostType":4,"repost":{"id":"2292286774","pubTimestamp":1671422971,"share":"https://www.laohu8.com/m/news/2292286774?lang=&edition=full","pubTime":"2022-12-19 12:09","market":"us","language":"en","title":"2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2292286774","media":"Motley Fool","summary":"These stocks look cheap -- especially considering their long-term potential.","content":"<html><head></head><body><p>You may see a lot of bargains in the shops and online this season. But there&#39;s an even better place to find a good deal these days. I&#39;m talking about the stock market. This year&#39;s long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.</p><p><i>&#34;But what if these stocks fall even further?&#34;</i> you might wonder. Well, it&#39;s impossible to effectively time the market, and it&#39;s a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you&#39;ll still benefit even if you didn&#39;t buy them at their cyclical low points.</p><p>If you&#39;re ready to give this winning strategy a try, here are two smart stocks I&#39;d recommend buying before the new year.</p><h2>1. Teladoc Health</h2><p><b>Teladoc Health</b> stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc&#39;s visits and revenue climbed by triple-digit percentages.</p><p>But the company has demonstrated it isn&#39;t a pandemic-only business. Teladoc&#39;s revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.</p><p>Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.</p><p>So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.</p><p>The third quarter brought investors some good news. Teladoc&#39;s loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.</p><p>Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it&#39;s expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.</p><p>Today, Teladoc shares are trading at their cheapest level <i>ever</i> in relation to sales. This is a major bargain considering the company&#39;s long-term potential.</p><h2>2. Abbott Laboratories</h2><p>There are two reasons to like <b>Abbott Laboratories</b>. First, let&#39;s talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it&#39;s particularly nice to have this guaranteed income during tough market times.</p><p>And Abbott isn&#39;t just a dividend stock -- it&#39;s a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.</p><p>Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.</p><p>Abbott has grown its free cash flow and return on invested capital over time.</p><p><img src=\"https://static.tigerbbs.com/053ae37cdf88229d770c12540a333184\" tg-width=\"720\" tg-height=\"463\" referrerpolicy=\"no-referrer\"/></p><p>ABT Free Cash Flow data by YCharts.</p><p>And it recently increased its full-year earnings-per-share forecast.</p><p>All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today&#39;s valuation of 20 times forward earnings estimates, Abbott&#39;s a stock you won&#39;t want to miss.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-19 12:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABT":"雅培","TDOC":"Teladoc Health Inc."},"source_url":"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2292286774","content_text":"You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.\"But what if these stocks fall even further?\" you might wonder. Well, it's impossible to effectively time the market, and it's a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you'll still benefit even if you didn't buy them at their cyclical low points.If you're ready to give this winning strategy a try, here are two smart stocks I'd recommend buying before the new year.1. Teladoc HealthTeladoc Health stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc's visits and revenue climbed by triple-digit percentages.But the company has demonstrated it isn't a pandemic-only business. Teladoc's revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.The third quarter brought investors some good news. Teladoc's loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it's expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.Today, Teladoc shares are trading at their cheapest level ever in relation to sales. This is a major bargain considering the company's long-term potential.2. Abbott LaboratoriesThere are two reasons to like Abbott Laboratories. First, let's talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it's particularly nice to have this guaranteed income during tough market times.And Abbott isn't just a dividend stock -- it's a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.Abbott has grown its free cash flow and return on invested capital over time.ABT Free Cash Flow data by YCharts.And it recently increased its full-year earnings-per-share forecast.All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today's valuation of 20 times forward earnings estimates, Abbott's a stock you won't want to miss.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":105258776,"gmtCreate":1671425064225,"gmtModify":1671425076905,"authorId":3581989576547489,"author":{"id":3581989576547489,"authorId":3581989576547489,"name":"SimonTan91","avatar":"https://static.tigerbbs.com/33a746662324e75f8c65f010f1588b16","vip":1,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9926021180,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":9926064416,"gmtCreate":1671423161836,"gmtModify":1676538534081,"author":{"id":"3582617881962608","authorId":"3582617881962608","name":"Ahsiang","avatar":"https://static.tigerbbs.com/310f96e7696af85ae33ece774a483d15","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Sure anot","listText":"Sure anot","text":"Sure anot","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/9926064416","repostId":2292286774,"repostType":4,"repost":{"id":"2292286774","pubTimestamp":1671422971,"share":"https://www.laohu8.com/m/news/2292286774?lang=&edition=full","pubTime":"2022-12-19 12:09","market":"us","language":"en","title":"2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2292286774","media":"Motley Fool","summary":"These stocks look cheap -- especially considering their long-term potential.","content":"<html><head></head><body><p>You may see a lot of bargains in the shops and online this season. But there&#39;s an even better place to find a good deal these days. I&#39;m talking about the stock market. This year&#39;s long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.</p><p><i>&#34;But what if these stocks fall even further?&#34;</i> you might wonder. Well, it&#39;s impossible to effectively time the market, and it&#39;s a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you&#39;ll still benefit even if you didn&#39;t buy them at their cyclical low points.</p><p>If you&#39;re ready to give this winning strategy a try, here are two smart stocks I&#39;d recommend buying before the new year.</p><h2>1. Teladoc Health</h2><p><b>Teladoc Health</b> stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc&#39;s visits and revenue climbed by triple-digit percentages.</p><p>But the company has demonstrated it isn&#39;t a pandemic-only business. Teladoc&#39;s revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.</p><p>Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.</p><p>So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.</p><p>The third quarter brought investors some good news. Teladoc&#39;s loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.</p><p>Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it&#39;s expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.</p><p>Today, Teladoc shares are trading at their cheapest level <i>ever</i> in relation to sales. This is a major bargain considering the company&#39;s long-term potential.</p><h2>2. Abbott Laboratories</h2><p>There are two reasons to like <b>Abbott Laboratories</b>. First, let&#39;s talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it&#39;s particularly nice to have this guaranteed income during tough market times.</p><p>And Abbott isn&#39;t just a dividend stock -- it&#39;s a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.</p><p>Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.</p><p>Abbott has grown its free cash flow and return on invested capital over time.</p><p><img src=\"https://static.tigerbbs.com/053ae37cdf88229d770c12540a333184\" tg-width=\"720\" tg-height=\"463\" referrerpolicy=\"no-referrer\"/></p><p>ABT Free Cash Flow data by YCharts.</p><p>And it recently increased its full-year earnings-per-share forecast.</p><p>All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today&#39;s valuation of 20 times forward earnings estimates, Abbott&#39;s a stock you won&#39;t want to miss.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-19 12:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABT":"雅培","TDOC":"Teladoc Health Inc."},"source_url":"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2292286774","content_text":"You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.\"But what if these stocks fall even further?\" you might wonder. Well, it's impossible to effectively time the market, and it's a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you'll still benefit even if you didn't buy them at their cyclical low points.If you're ready to give this winning strategy a try, here are two smart stocks I'd recommend buying before the new year.1. Teladoc HealthTeladoc Health stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc's visits and revenue climbed by triple-digit percentages.But the company has demonstrated it isn't a pandemic-only business. Teladoc's revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.The third quarter brought investors some good news. Teladoc's loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it's expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.Today, Teladoc shares are trading at their cheapest level ever in relation to sales. This is a major bargain considering the company's long-term potential.2. Abbott LaboratoriesThere are two reasons to like Abbott Laboratories. First, let's talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it's particularly nice to have this guaranteed income during tough market times.And Abbott isn't just a dividend stock -- it's a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.Abbott has grown its free cash flow and return on invested capital over time.ABT Free Cash Flow data by YCharts.And it recently increased its full-year earnings-per-share forecast.All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today's valuation of 20 times forward earnings estimates, Abbott's a stock you won't want to miss.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":105258844,"gmtCreate":1671425829260,"gmtModify":1671425842899,"authorId":3585789628360174,"author":{"id":3585789628360174,"authorId":3585789628360174,"name":"Meowlisa","avatar":"https://community-static.tradeup.com/news/d4201545a2ca6590a1c7760d87393e86","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9926064416,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Ok</span>","text":"<span class=\"s1\">Ok</span>","html":"<span class=\"s1\">Ok</span>"},{"id":105258465,"gmtCreate":1671423864974,"gmtModify":1671423877849,"authorId":3565425398867432,"author":{"id":3565425398867432,"authorId":3565425398867432,"name":"Alfred8189","avatar":"https://static.tigerbbs.com/65653d3db531b1ead6e47420db3271b0","vip":1,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":5,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9926064416,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Ok</span>","text":"<span class=\"s1\">Ok</span>","html":"<span class=\"s1\">Ok</span>"},{"id":105258365,"gmtCreate":1671423431439,"gmtModify":1671423444774,"authorId":3579683280519440,"author":{"id":3579683280519440,"authorId":3579683280519440,"name":"jingabel","avatar":"https://static.tigerbbs.com/5109716c64f0b691a5098e4d5397ffc2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9926064416,"type":1,"supId":0,"prevId":0,"content":"k","text":"k","html":"k"}],"langContent":"EN"},{"id":9926097089,"gmtCreate":1671415785041,"gmtModify":1676538532578,"author":{"id":"3581548481060535","authorId":"3581548481060535","name":"Butt3rc00ki3","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9926097089","repostId":2292286774,"repostType":4,"repost":{"id":"2292286774","pubTimestamp":1671422971,"share":"https://www.laohu8.com/m/news/2292286774?lang=&edition=full","pubTime":"2022-12-19 12:09","market":"us","language":"en","title":"2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2292286774","media":"Motley Fool","summary":"These stocks look cheap -- especially considering their long-term potential.","content":"<html><head></head><body><p>You may see a lot of bargains in the shops and online this season. But there&#39;s an even better place to find a good deal these days. I&#39;m talking about the stock market. This year&#39;s long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.</p><p><i>&#34;But what if these stocks fall even further?&#34;</i> you might wonder. Well, it&#39;s impossible to effectively time the market, and it&#39;s a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you&#39;ll still benefit even if you didn&#39;t buy them at their cyclical low points.</p><p>If you&#39;re ready to give this winning strategy a try, here are two smart stocks I&#39;d recommend buying before the new year.</p><h2>1. Teladoc Health</h2><p><b>Teladoc Health</b> stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc&#39;s visits and revenue climbed by triple-digit percentages.</p><p>But the company has demonstrated it isn&#39;t a pandemic-only business. Teladoc&#39;s revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.</p><p>Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.</p><p>So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.</p><p>The third quarter brought investors some good news. Teladoc&#39;s loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.</p><p>Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it&#39;s expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.</p><p>Today, Teladoc shares are trading at their cheapest level <i>ever</i> in relation to sales. This is a major bargain considering the company&#39;s long-term potential.</p><h2>2. Abbott Laboratories</h2><p>There are two reasons to like <b>Abbott Laboratories</b>. First, let&#39;s talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it&#39;s particularly nice to have this guaranteed income during tough market times.</p><p>And Abbott isn&#39;t just a dividend stock -- it&#39;s a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.</p><p>Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.</p><p>Abbott has grown its free cash flow and return on invested capital over time.</p><p><img src=\"https://static.tigerbbs.com/053ae37cdf88229d770c12540a333184\" tg-width=\"720\" tg-height=\"463\" referrerpolicy=\"no-referrer\"/></p><p>ABT Free Cash Flow data by YCharts.</p><p>And it recently increased its full-year earnings-per-share forecast.</p><p>All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today&#39;s valuation of 20 times forward earnings estimates, Abbott&#39;s a stock you won&#39;t want to miss.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-19 12:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABT":"雅培","TDOC":"Teladoc Health Inc."},"source_url":"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2292286774","content_text":"You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.\"But what if these stocks fall even further?\" you might wonder. Well, it's impossible to effectively time the market, and it's a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you'll still benefit even if you didn't buy them at their cyclical low points.If you're ready to give this winning strategy a try, here are two smart stocks I'd recommend buying before the new year.1. Teladoc HealthTeladoc Health stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc's visits and revenue climbed by triple-digit percentages.But the company has demonstrated it isn't a pandemic-only business. Teladoc's revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.The third quarter brought investors some good news. Teladoc's loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it's expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.Today, Teladoc shares are trading at their cheapest level ever in relation to sales. This is a major bargain considering the company's long-term potential.2. Abbott LaboratoriesThere are two reasons to like Abbott Laboratories. First, let's talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it's particularly nice to have this guaranteed income during tough market times.And Abbott isn't just a dividend stock -- it's a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.Abbott has grown its free cash flow and return on invested capital over time.ABT Free Cash Flow data by YCharts.And it recently increased its full-year earnings-per-share forecast.All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today's valuation of 20 times forward earnings estimates, Abbott's a stock you won't want to miss.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":105256114,"gmtCreate":1671415840121,"gmtModify":1671415853597,"authorId":4100348078055020,"author":{"id":4100348078055020,"authorId":4100348078055020,"name":"Mad Hatter","avatar":"https://static.itradeup.com/news/7d8d975059961b9fe0ed9145724726df","vip":1,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9926097089,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Ok</span>","text":"<span class=\"s1\">Ok</span>","html":"<span class=\"s1\">Ok</span>"}],"langContent":"EN"},{"id":9926095100,"gmtCreate":1671415635501,"gmtModify":1676538532515,"author":{"id":"4107301244908230","authorId":"4107301244908230","name":"ops22","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9926095100","repostId":2292286774,"repostType":4,"repost":{"id":"2292286774","pubTimestamp":1671422971,"share":"https://www.laohu8.com/m/news/2292286774?lang=&edition=full","pubTime":"2022-12-19 12:09","market":"us","language":"en","title":"2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2292286774","media":"Motley Fool","summary":"These stocks look cheap -- especially considering their long-term potential.","content":"<html><head></head><body><p>You may see a lot of bargains in the shops and online this season. But there&#39;s an even better place to find a good deal these days. I&#39;m talking about the stock market. This year&#39;s long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.</p><p><i>&#34;But what if these stocks fall even further?&#34;</i> you might wonder. Well, it&#39;s impossible to effectively time the market, and it&#39;s a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you&#39;ll still benefit even if you didn&#39;t buy them at their cyclical low points.</p><p>If you&#39;re ready to give this winning strategy a try, here are two smart stocks I&#39;d recommend buying before the new year.</p><h2>1. Teladoc Health</h2><p><b>Teladoc Health</b> stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc&#39;s visits and revenue climbed by triple-digit percentages.</p><p>But the company has demonstrated it isn&#39;t a pandemic-only business. Teladoc&#39;s revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.</p><p>Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.</p><p>So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.</p><p>The third quarter brought investors some good news. Teladoc&#39;s loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.</p><p>Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it&#39;s expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.</p><p>Today, Teladoc shares are trading at their cheapest level <i>ever</i> in relation to sales. This is a major bargain considering the company&#39;s long-term potential.</p><h2>2. Abbott Laboratories</h2><p>There are two reasons to like <b>Abbott Laboratories</b>. First, let&#39;s talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it&#39;s particularly nice to have this guaranteed income during tough market times.</p><p>And Abbott isn&#39;t just a dividend stock -- it&#39;s a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.</p><p>Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.</p><p>Abbott has grown its free cash flow and return on invested capital over time.</p><p><img src=\"https://static.tigerbbs.com/053ae37cdf88229d770c12540a333184\" tg-width=\"720\" tg-height=\"463\" referrerpolicy=\"no-referrer\"/></p><p>ABT Free Cash Flow data by YCharts.</p><p>And it recently increased its full-year earnings-per-share forecast.</p><p>All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today&#39;s valuation of 20 times forward earnings estimates, Abbott&#39;s a stock you won&#39;t want to miss.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-19 12:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABT":"雅培","TDOC":"Teladoc Health Inc."},"source_url":"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2292286774","content_text":"You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.\"But what if these stocks fall even further?\" you might wonder. Well, it's impossible to effectively time the market, and it's a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you'll still benefit even if you didn't buy them at their cyclical low points.If you're ready to give this winning strategy a try, here are two smart stocks I'd recommend buying before the new year.1. Teladoc HealthTeladoc Health stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc's visits and revenue climbed by triple-digit percentages.But the company has demonstrated it isn't a pandemic-only business. Teladoc's revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.The third quarter brought investors some good news. Teladoc's loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it's expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.Today, Teladoc shares are trading at their cheapest level ever in relation to sales. This is a major bargain considering the company's long-term potential.2. Abbott LaboratoriesThere are two reasons to like Abbott Laboratories. First, let's talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it's particularly nice to have this guaranteed income during tough market times.And Abbott isn't just a dividend stock -- it's a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.Abbott has grown its free cash flow and return on invested capital over time.ABT Free Cash Flow data by YCharts.And it recently increased its full-year earnings-per-share forecast.All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today's valuation of 20 times forward earnings estimates, Abbott's a stock you won't want to miss.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":105258443,"gmtCreate":1671423727248,"gmtModify":1671423740487,"authorId":3581838843201713,"author":{"id":3581838843201713,"authorId":3581838843201713,"name":"Veldin","avatar":"https://static.tigerbbs.com/1066c001ce0c01a3b97656619c989986","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.06%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9926095100,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Sew</span>","text":"<span class=\"s1\">Sew</span>","html":"<span class=\"s1\">Sew</span>"},{"id":105255986,"gmtCreate":1671415674986,"gmtModify":1671415686897,"authorId":3569225668665653,"author":{"id":3569225668665653,"authorId":3569225668665653,"name":"ZachLoh","avatar":"https://static.tigerbbs.com/39ae35b0a4b7e22dee7378b1bc1de2f6","vip":1,"currentWearingBadge":{"badgeId":"23f878ed27704312ae41c7f17e73b319-6","templateUuid":"23f878ed27704312ae41c7f17e73b319","name":"Annualised return","description":"Top 3%","bigImgUrl":"https://community-static.tradeup.com/news/6fbaa8e552e02eae8e6a2ce5d6566431","smallImgUrl":"https://community-static.tradeup.com/news/98862e418516dab972bed7aaf561dec6","grayImgUrl":"https://community-static.tradeup.com/news/3a5ca933a5695ed2e862b228f6c09ee5","redirectLinkEnabled":1,"redirectLink":"https://www.tigerbrokers.com.sg/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.08.30","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":5300},"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9926095100,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Ok</span>","text":"<span class=\"s1\">Ok</span>","html":"<span class=\"s1\">Ok</span>"}],"langContent":"EN"},{"id":9926092881,"gmtCreate":1671415571344,"gmtModify":1676538532489,"author":{"id":"3586969379790251","authorId":"3586969379790251","name":"Dragonroar","avatar":"https://static.tigerbbs.com/c85f59035023e669e7f4f44f503edbbe","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9926092881","repostId":2292286774,"repostType":4,"repost":{"id":"2292286774","pubTimestamp":1671422971,"share":"https://www.laohu8.com/m/news/2292286774?lang=&edition=full","pubTime":"2022-12-19 12:09","market":"us","language":"en","title":"2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2292286774","media":"Motley Fool","summary":"These stocks look cheap -- especially considering their long-term potential.","content":"<html><head></head><body><p>You may see a lot of bargains in the shops and online this season. But there&#39;s an even better place to find a good deal these days. I&#39;m talking about the stock market. This year&#39;s long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.</p><p><i>&#34;But what if these stocks fall even further?&#34;</i> you might wonder. Well, it&#39;s impossible to effectively time the market, and it&#39;s a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you&#39;ll still benefit even if you didn&#39;t buy them at their cyclical low points.</p><p>If you&#39;re ready to give this winning strategy a try, here are two smart stocks I&#39;d recommend buying before the new year.</p><h2>1. Teladoc Health</h2><p><b>Teladoc Health</b> stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc&#39;s visits and revenue climbed by triple-digit percentages.</p><p>But the company has demonstrated it isn&#39;t a pandemic-only business. Teladoc&#39;s revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.</p><p>Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.</p><p>So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.</p><p>The third quarter brought investors some good news. Teladoc&#39;s loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.</p><p>Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it&#39;s expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.</p><p>Today, Teladoc shares are trading at their cheapest level <i>ever</i> in relation to sales. This is a major bargain considering the company&#39;s long-term potential.</p><h2>2. Abbott Laboratories</h2><p>There are two reasons to like <b>Abbott Laboratories</b>. First, let&#39;s talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it&#39;s particularly nice to have this guaranteed income during tough market times.</p><p>And Abbott isn&#39;t just a dividend stock -- it&#39;s a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.</p><p>Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.</p><p>Abbott has grown its free cash flow and return on invested capital over time.</p><p><img src=\"https://static.tigerbbs.com/053ae37cdf88229d770c12540a333184\" tg-width=\"720\" tg-height=\"463\" referrerpolicy=\"no-referrer\"/></p><p>ABT Free Cash Flow data by YCharts.</p><p>And it recently increased its full-year earnings-per-share forecast.</p><p>All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today&#39;s valuation of 20 times forward earnings estimates, Abbott&#39;s a stock you won&#39;t want to miss.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-19 12:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABT":"雅培","TDOC":"Teladoc Health Inc."},"source_url":"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2292286774","content_text":"You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.\"But what if these stocks fall even further?\" you might wonder. Well, it's impossible to effectively time the market, and it's a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you'll still benefit even if you didn't buy them at their cyclical low points.If you're ready to give this winning strategy a try, here are two smart stocks I'd recommend buying before the new year.1. Teladoc HealthTeladoc Health stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc's visits and revenue climbed by triple-digit percentages.But the company has demonstrated it isn't a pandemic-only business. Teladoc's revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.The third quarter brought investors some good news. Teladoc's loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it's expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.Today, Teladoc shares are trading at their cheapest level ever in relation to sales. This is a major bargain considering the company's long-term potential.2. Abbott LaboratoriesThere are two reasons to like Abbott Laboratories. First, let's talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it's particularly nice to have this guaranteed income during tough market times.And Abbott isn't just a dividend stock -- it's a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.Abbott has grown its free cash flow and return on invested capital over time.ABT Free Cash Flow data by YCharts.And it recently increased its full-year earnings-per-share forecast.All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today's valuation of 20 times forward earnings estimates, Abbott's a stock you won't want to miss.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":105267187,"gmtCreate":1671493116223,"gmtModify":1671493129030,"authorId":3582101321255914,"author":{"id":3582101321255914,"authorId":3582101321255914,"name":"鸟雨花香","avatar":"https://static.tigerbbs.com/98b16b55879fd1a4b831b436592733a7","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9926092881,"type":1,"supId":0,"prevId":0,"content":"👍","text":"👍","html":"👍"},{"id":105255978,"gmtCreate":1671415659095,"gmtModify":1671415674778,"authorId":4107301244908230,"author":{"id":4107301244908230,"authorId":4107301244908230,"name":"ops22","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9926092881,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":9926096647,"gmtCreate":1671415451589,"gmtModify":1676538532454,"author":{"id":"3569303342488537","authorId":"3569303342488537","name":"ColeHii","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":1},"htmlText":"🇦🇷","listText":"🇦🇷","text":"🇦🇷","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9926096647","repostId":2292286774,"repostType":4,"repost":{"id":"2292286774","pubTimestamp":1671422971,"share":"https://www.laohu8.com/m/news/2292286774?lang=&edition=full","pubTime":"2022-12-19 12:09","market":"us","language":"en","title":"2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2292286774","media":"Motley Fool","summary":"These stocks look cheap -- especially considering their long-term potential.","content":"<html><head></head><body><p>You may see a lot of bargains in the shops and online this season. But there&#39;s an even better place to find a good deal these days. I&#39;m talking about the stock market. This year&#39;s long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.</p><p><i>&#34;But what if these stocks fall even further?&#34;</i> you might wonder. Well, it&#39;s impossible to effectively time the market, and it&#39;s a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you&#39;ll still benefit even if you didn&#39;t buy them at their cyclical low points.</p><p>If you&#39;re ready to give this winning strategy a try, here are two smart stocks I&#39;d recommend buying before the new year.</p><h2>1. Teladoc Health</h2><p><b>Teladoc Health</b> stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc&#39;s visits and revenue climbed by triple-digit percentages.</p><p>But the company has demonstrated it isn&#39;t a pandemic-only business. Teladoc&#39;s revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.</p><p>Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.</p><p>So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.</p><p>The third quarter brought investors some good news. Teladoc&#39;s loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.</p><p>Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it&#39;s expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.</p><p>Today, Teladoc shares are trading at their cheapest level <i>ever</i> in relation to sales. This is a major bargain considering the company&#39;s long-term potential.</p><h2>2. Abbott Laboratories</h2><p>There are two reasons to like <b>Abbott Laboratories</b>. First, let&#39;s talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it&#39;s particularly nice to have this guaranteed income during tough market times.</p><p>And Abbott isn&#39;t just a dividend stock -- it&#39;s a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.</p><p>Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.</p><p>Abbott has grown its free cash flow and return on invested capital over time.</p><p><img src=\"https://static.tigerbbs.com/053ae37cdf88229d770c12540a333184\" tg-width=\"720\" tg-height=\"463\" referrerpolicy=\"no-referrer\"/></p><p>ABT Free Cash Flow data by YCharts.</p><p>And it recently increased its full-year earnings-per-share forecast.</p><p>All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today&#39;s valuation of 20 times forward earnings estimates, Abbott&#39;s a stock you won&#39;t want to miss.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-19 12:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABT":"雅培","TDOC":"Teladoc Health Inc."},"source_url":"https://www.fool.com/investing/2022/12/18/bargain-shopping-2-smart-stocks-to-buy-before-2023/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2292286774","content_text":"You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.\"But what if these stocks fall even further?\" you might wonder. Well, it's impossible to effectively time the market, and it's a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you'll still benefit even if you didn't buy them at their cyclical low points.If you're ready to give this winning strategy a try, here are two smart stocks I'd recommend buying before the new year.1. Teladoc HealthTeladoc Health stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc's visits and revenue climbed by triple-digit percentages.But the company has demonstrated it isn't a pandemic-only business. Teladoc's revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.The third quarter brought investors some good news. Teladoc's loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it's expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.Today, Teladoc shares are trading at their cheapest level ever in relation to sales. This is a major bargain considering the company's long-term potential.2. Abbott LaboratoriesThere are two reasons to like Abbott Laboratories. First, let's talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it's particularly nice to have this guaranteed income during tough market times.And Abbott isn't just a dividend stock -- it's a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.Abbott has grown its free cash flow and return on invested capital over time.ABT Free Cash Flow data by YCharts.And it recently increased its full-year earnings-per-share forecast.All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today's valuation of 20 times forward earnings estimates, Abbott's a stock you won't want to miss.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":105255923,"gmtCreate":1671415578397,"gmtModify":1671415593264,"authorId":3556192689502522,"author":{"id":3556192689502522,"authorId":3556192689502522,"name":"LuciusCY","avatar":"https://static.tigerbbs.com/057fde93bb35d7c5933092f2938d93a1","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9926096647,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":366,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}